Approval · Notice of Compliance 32905 · 2024
APO-TOFACITINIB: Notice of Compliance 32905
Issued March 15, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32905
- Date
- March 15, 2024
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
- Canadian reference product
- XELJANZ (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-TOFACITINIB | Not yet assigned | — |
Medicinal ingredients
- TOFACITINIB CITRATE 5 MG per TAB
- TOFACITINIB CITRATE 10 MG per TAB